Skip Navigation


Hum. Reprod. Advance Access originally published online on April 7, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
19/5/1110    most recent
deh219v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Farquhar, C. M.
Right arrow Articles by Garland, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farquhar, C. M.
Right arrow Articles by Garland, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 19, No. 5, 1110-1115, May 2004
© 2004 European Society of Human Reproduction and Embryology

An economic evaluation of laparoscopic ovarian diathermy versus gonadotrophin therapy for women with clomiphene citrate resistant polycystic ovary syndrome

Cynthia M. Farquhar1,2,3,5, Karen Williamson1, Paul M. Brown3,4 and Jules Garland1

1 Department of Obstetrics & Gynaecology, 2 Fertility Plus, 3 Effective Practice, Informatics and Quality Institute, University of Auckland, Auckland, New Zealand and 4 Centre for Health Services Research and Policy

5 To whom correspondence should be addressed at: Department of Obstetrics & Gynaecology, University of Auckland, National Womens Hospital, Auckland, New Zealand. e-mail: c.farquhar{at}auckland.ac.nz

BACKGROUND: Laparoscopic ovarian diathermy and gonadotrophin ovulation induction for women with clomiphene citrate resistant polycystic ovary syndrome have been shown to result in similar pregnancy rates, but their relative cost-effectiveness has not been evaluated. METHODS: A cost-minimization study was undertaken alongside a randomized controlled trial in women with anovulatory infertility secondary to clomiphene resistant polycystic ovary syndrome. Inclusion criteria were age less than 39 years, body mass index less than 35 kg/m2, failure to ovulate with 150 mg of clomiphene citrate for 5 days in the early follicular phase, more than 12 months of infertility and no other causes of infertility. Laparoscopic ovarian diathermy was compared with three cycles of urinary or recombinant gonadotrophins. Direct and indirect costs were based on the results of a randomized trial. Results: The cost of a live birth was one third lower in the group that underwent laparoscopic ovarian diathermy compared to those women who received gonadotrophins (NZ$19 640 and NZ$29 836, respectively). Conclusions: This economic evaluation shows that treating women with clomiphene-resistant polycystic ovarian syndrome with laparoscopic ovarian diathermy results in a significant reduction in both direct and indirect costs.

Key words: clomiphene citrate resistance/cost-effectiveness analysis/gonadotrophins/laparoscopic ovarian diathermy/polycystic ovary syndrome


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consens
Consensus on infertility treatment related to polycystic ovary syndrome
Hum. Reprod., March 1, 2008; 23(3): 462 - 477.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.